Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V. In 2021, the Group’s net sales totaled EUR 78.8 million, with an operating profit of EUR 22.1 million. iCare Solutions provide digital clinical tools that drive greater efficiency and enhance quality in eye care. iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for the diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand. Find related and similar companies as well as. Revenio is a leading company in the global market for ophthalmological devices and software solutions. View iCare Solutions (location in Egypt, revenue, industry and description. +358 Principal media Revenio Group in brief More information on iCare ILLUME can be found at For further information, please contact Vice President, Sales & Marketing Tomi Karvo tel. Our software solutions are playing an increasingly important role in eye care pathways, and we continue to be the trusted developer for ophthalmic diagnostic devices.” Revenio Group CEO Jouni Toijala comments: “Diabetes prevalence is increasing fast globally, and the world needs innovative solutions so screening coverage can be increased, and at the same time ophthalmologists can focus on the patients with real signs of eye diseases. Digital tools that connect eye care pathways are the answer to increasing productivity while maintaining a high quality of care. iCare Solutions pairs high-quality fundus imaging systems and tonometers with intuitive, user-friendly, and secure clinical software. ICare Solutions provides digital clinical tools that drive greater efficiency, enhance quality in eye care, and mean that health care professionals can provide care to a greater number of patients. With its electrifying presence, Icare Solution LLC has swirled the scenario of total web solutions. The iCare ILLUME solution can be used for screening other eye diseases in the future. This allows the utilization of the high-quality images generated by the iCare DRSplus fundus imaging system even more extensively as support for clinical decision-making. Retina images taken with the iCare DRSplus fundus imaging system are automatically transferred to iCare ILLUME solution cloud service and the report is instantly available. iCare ILLUME instantly detects signs of vision-threatening diabetic retinopathy with AI. ICare ILLUME is a unique combination of specialized screening software with artificial intelligence (AI) by our partner Thirona and iCare DRSplus fundus imaging system with TrueColor Confocal capabilities. ICare ILLUME, a screening solution using artificial intelligence, has been launched today as part of iCare Solutions. A new host of personalized software services promoting the digital transformation of Healthcare, Education, and Insurance. Joining forces with innovative partners that complement our strengths, capabilities and commitments to eye care, including our work in chronic retinal diseases with REGENXBIO.ICare ILLUME, a screening solution using artificial intelligence has been launched today Working with colleagues across AbbVie to seize the scientific opportunity of innovation within oncology, immunology and neuroscience through knowledge of common disease pathways.Īpplying state-of-the-art imaging modalities to monitor disease progression and therapeutic intervention to accelerate the translation of bench science to the clinic. Leading innovation in long-acting therapeutic approaches via mechanism of action, sustained-release formulations or gene therapy to reduce the treatment burden. Our research interests include:īridging our understanding of biological processes and the genetic basis of human disease to accelerate ophthalmic drug discovery. Our research, focused on unmet needs, fuels an innovative pipeline of treatments that seek to preserve and protect vision and prevent blindness. Our robust research and development approach is anchored in improving the standards of care across multiple disease areas to make a meaningful difference for patients. Each year more people will receive a vision-threatening diagnosis due to aging and lifestyle factors.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |